Endo’s Testosterone REMS, Revised Dosing Don’t Solve FDA Concerns

FDA briefing documents for the advisory committee review of Endo’s Aveed cite the “excessive burden” imposed by any one of the REMS restrictive elements, given the injectable testosterone’s limited additional benefit compared to other available treatment options.